We confirmed the metabolic impact of LDHA inhibition in several primary AML patient blasts (AML4, AML6, AML11; see Fig. 1H and Supplementary Table 1) that, when treated with GSK2837808A, significantly reduced their ECAR and increased the OCR (Fig. 2G, H). The gene discussed is LDHA; the disease is acute myeloid leukemia.